Raymond James Financial
IKT icon

Raymond James Financial’s Inhibikase Therapeutics IKT Stock Holding History

Raymond James Financial’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$1.95K – 5798
2025
Q2 		$1.95K Buy
+1,000
New +$1.96K ﹤0.01% 6417

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Raymond James Financial's IKT Position: Q3 2025 in Review

Raymond James Financial sold out of Inhibikase Therapeutics (IKT) in Q3 2025, closing a stake of 1,000 shares — an estimated $1.95K sold.

Raymond James Financial first reported a position in IKT in Q2 2025 and held it in 1 quarter. The position peaked at $1.95K in Q2 2025. 54 funds tracked by Wall St. Rank hold IKT as of Q3 2025.

  • Raymond James Financial reported no remaining Inhibikase Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,000 Inhibikase Therapeutics shares in Q3 2025, an estimated $1.95K.
  • Raymond James Financial first reported a position in Inhibikase Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Inhibikase Therapeutics position peaked at $1.95K in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.